<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00704405</url>
  </required_header>
  <id_info>
    <org_study_id>7009-009</org_study_id>
    <secondary_id>2007_659</secondary_id>
    <nct_id>NCT00704405</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)</brief_title>
  <official_title>A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Experienced Patients With Chronic Genotype 1 Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety, tolerability, and efficacy of 4 regimens of
      Vaniprevir + Peg-IFN and Ribavirin as compared to Placebo (PBO) + Peg-IFN/RBV. The primary
      hypotheses are that Vaniprevir is well tolerated, and that Vaniprevir 600 mg twice daily
      (b.i.d.) is superior to the control regimen for the percentage of non-cirrhotic (NC)
      participants achieving undetectable HCV ribonucleic acid (RNA) 24 weeks after the end of
      study therapy (SVR24).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 600 mg b.i.d.</measure>
    <time_frame>Up to 72 weeks</time_frame>
    <description>The percentage of non-cirrhotic participants with undetectable Hepatits C virus (HCV) ribonucleic acid (RNA) 24 weeks after completing treatment was determined for each Vaniprevir 600 mg b.i.d. and control regimen. Results for Vaniprevir 300 mg are presented as a Secondary Outcome Measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to 73 weeks</time_frame>
    <description>The number of non-cirrhotic participants experiencing AEs during the active Vaniprevir/PBO treatment and 14-day follow-up periods was monitored for each treatment regimen. An AE was defined as any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a Sponsor product, whether or not considered related to the use of the product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing From Study Treatment Due to AEs</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>The number of non-cirrhotic participants withdrawing from study treatment due to AEs during the active Vaniprevir/PBO treatment and 14-day follow-up periods was monitored for each treatment regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 300 mg b.i.d.</measure>
    <time_frame>72 weeks</time_frame>
    <description>The percentage of non-cirrhotic participants treated with Vaniprevir 300 mg b.i.d. with undetectable HCV RNA 24 weeks after completing treatment was determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving cEVR</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>The percentage of non-cirrhotic participants with complete early viral response (cEVR; undetectable HCV RNA at Week 12) was determined for each Vaniprevir dose. Since each of the Vaniprevir 600 mg arms had the same treatment history at this point in the study, the data were pooled for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SVR24 After 24 Weeks of Vaniprevir 600 mg b.i.d.</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants achieving SVR24 after the 24-week Vaniprevir 600 mg b.i.d. regimen at Week 48 was compared to the control regimen.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">285</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>24-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaniprevir 300 mg (total daily dose, taken once daily [q.d.]) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48-wk PBO + Peg-IFN/RBV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaniprevir</intervention_name>
    <description>Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.</description>
    <arm_group_label>24-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <other_name>MK-7009</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon (Peg-IFN)</intervention_name>
    <description>Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks</description>
    <arm_group_label>24-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk PBO + Peg-IFN/RBV</arm_group_label>
    <other_name>PEGASYS™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing &lt;=75 kg and 1200 mg for participants weighing &gt;75 kg.</description>
    <arm_group_label>24-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk PBO + Peg-IFN/RBV</arm_group_label>
    <other_name>COPEGUS™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (PBO)</intervention_name>
    <description>Participants took PBO capsules matching Vaniprevir capsules, three in the morning and three in the evening, for 24 or 48 weeks.</description>
    <arm_group_label>24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV</arm_group_label>
    <arm_group_label>48-wk PBO + Peg-IFN/RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Has chronic HCV genotype 1 infection

          -  Is treatment-experienced

          -  For the non-cirrhotic population, has had a liver biopsy without evidence of cirrhosis
             and hepatocellular carcinoma; for the cirrhotic population, has had a liver biopsy
             with evidence of cirrhosis and without evidence of hepatocellular carcinoma.

        Exclusion criteria:

          -  Has not tolerated previous course peg-IFN and RBV

          -  Is unlikely to tolerate at least 24 weeks of continuous therapy with Peg-IFN and RBV

          -  Is co-infected with Human Immunodeficiency Virus (HIV) and/or hepatitis B

          -  Consumes excessive amounts of alcohol

          -  Has a history of drug or alcohol abuse

          -  If female, participant is pregnant or breastfeeding

          -  Has been in a clinical trail with an investigational drug in the last 30 days

          -  Has used IFN/Peg-IFN and RBV in the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Lawitz E, Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Bhanja S, Barnard RJ, An D, Gress J, Hwang P, Mobashery N. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. J Hepatol. 2013 Jul;59(1):11-7. doi: 10.1016/j.jhep.2013.02.008. Epub 2013 Feb 21.</citation>
    <PMID>23439259</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Lawitz E, Zhou A, Bourque M, Bhanja S, Strizki J, Barnard RJ, Hwang PM, DiNubile MJ, Mobashery N. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clin Gastroenterol Hepatol. 2014 Jun;12(6):1029-37.e5. doi: 10.1016/j.cgh.2013.09.067. Epub 2013 Oct 10.</citation>
    <PMID>24120953</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2008</study_first_posted>
  <results_first_submitted>September 26, 2014</results_first_submitted>
  <results_first_submitted_qc>September 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 29, 2014</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=7009-009&amp;kw=7009-009&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Non-cirrhotic (NC) and cirrhotic (C) participants were screened and enrolled separately in this study. The NC population was used for all safety, tolerability, and efficacy outcome measures. Primary analyses of the outcome measures only included the NC population. Adverse events (AEs) were monitored in both the NC and C populations.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>24-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
          <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and peg-IFN 180 mcg injection once weekly for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>24-wk Vaniprevir 600 mg, 24-wk PBO + Peg-IFN/RBV</title>
          <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and peg-IFN 180 mcg injection once weekly for an additional 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</title>
          <description>Vaniprevir 300 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
        </group>
        <group group_id="P4">
          <title>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
          <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
        </group>
        <group group_id="P5">
          <title>48-wk PBO + Peg-IFN/RBV</title>
          <description>PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study (NC Population)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="42"/>
                <participants group_id="P5" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Overall Study (C Population)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Baseline Population consists of all randomized C and NC participants.</population>
      <group_list>
        <group group_id="B1">
          <title>24-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
          <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and peg-IFN 180 mcg injection once weekly for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>24-wk Vaniprevir 600 mg, 24-wk PBO + Peg-IFN/RBV</title>
          <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and peg-IFN 180 mcg injection once weekly for an additional 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</title>
          <description>Vaniprevir 300 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
        </group>
        <group group_id="B4">
          <title>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
          <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
        </group>
        <group group_id="B5">
          <title>48-wk PBO + Peg-IFN/RBV</title>
          <description>PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="56"/>
            <count group_id="B4" value="57"/>
            <count group_id="B5" value="56"/>
            <count group_id="B6" value="285"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0" spread="8.4"/>
                    <measurement group_id="B2" value="51.6" spread="8.1"/>
                    <measurement group_id="B3" value="50.6" spread="7.5"/>
                    <measurement group_id="B4" value="52.1" spread="8.7"/>
                    <measurement group_id="B5" value="49.9" spread="7.8"/>
                    <measurement group_id="B6" value="50.8" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 600 mg b.i.d.</title>
        <description>The percentage of non-cirrhotic participants with undetectable Hepatits C virus (HCV) ribonucleic acid (RNA) 24 weeks after completing treatment was determined for each Vaniprevir 600 mg b.i.d. and control regimen. Results for Vaniprevir 300 mg are presented as a Secondary Outcome Measure.</description>
        <time_frame>Up to 72 weeks</time_frame>
        <population>The Full Analysis Set (FAS) population consists of all non-cirrhotic participants who received at least 1 dose of study treatment, have post-dose endpoint data, and have baseline data for measures that require baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>24- or 48-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
            <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 or 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>24-wk Vaniprevir 600 mg, 24-wk PBO + Peg-IFN/RBV</title>
            <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
            <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>48-wk PBO + Peg-IFN/RBV</title>
            <description>PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 600 mg b.i.d.</title>
          <description>The percentage of non-cirrhotic participants with undetectable Hepatits C virus (HCV) ribonucleic acid (RNA) 24 weeks after completing treatment was determined for each Vaniprevir 600 mg b.i.d. and control regimen. Results for Vaniprevir 300 mg are presented as a Secondary Outcome Measure.</description>
          <population>The Full Analysis Set (FAS) population consists of all non-cirrhotic participants who received at least 1 dose of study treatment, have post-dose endpoint data, and have baseline data for measures that require baseline data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1"/>
                    <measurement group_id="O2" value="84.2"/>
                    <measurement group_id="O3" value="78.0"/>
                    <measurement group_id="O4" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen method</method>
            <param_type>Adjusted difference in percentage</param_type>
            <param_value>53.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34.5</ci_lower_limit>
            <ci_upper_limit>69.1</ci_upper_limit>
            <estimate_desc>Adjusted difference subtracts the percentage of PBO-treated participants (i.e., 19.0%) that achieved SVR24 and stratifies by prior treatment response.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen method</method>
            <param_type>Adjusted difference in percentage</param_type>
            <param_value>64.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>45.2</ci_lower_limit>
            <ci_upper_limit>78.3</ci_upper_limit>
            <estimate_desc>Adjusted difference subtracts the percentage of PBO-treated participants (i.e., 19.0%) that achieved SVR24 and stratifies by prior treatment response.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted difference in percentage</param_type>
            <param_value>59.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40.2</ci_lower_limit>
            <ci_upper_limit>73.4</ci_upper_limit>
            <estimate_desc>Adjusted difference subtracts the percentage of PBO-treated participants (i.e., 19.0%) that achieved SVR24 and stratifies by prior treatment response.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing an Adverse Event (AE)</title>
        <description>The number of non-cirrhotic participants experiencing AEs during the active Vaniprevir/PBO treatment and 14-day follow-up periods was monitored for each treatment regimen. An AE was defined as any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a Sponsor product, whether or not considered related to the use of the product.</description>
        <time_frame>Up to 73 weeks</time_frame>
        <population>The All-Patients-as-Treated (APaT) population was employed for safety analyses. The APaT population consists of all non-cirrhotic randomized patients who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>24- or 48-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
            <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 or 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>24-wk Vaniprevir 600 mg, 24-wk PBO + Peg-IFN/RBV</title>
            <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</title>
            <description>Vaniprevir 300 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
            <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
          </group>
          <group group_id="O5">
            <title>48-wk PBO + Peg-IFN/RBV</title>
            <description>PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing an Adverse Event (AE)</title>
          <description>The number of non-cirrhotic participants experiencing AEs during the active Vaniprevir/PBO treatment and 14-day follow-up periods was monitored for each treatment regimen. An AE was defined as any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a Sponsor product, whether or not considered related to the use of the product.</description>
          <population>The All-Patients-as-Treated (APaT) population was employed for safety analyses. The APaT population consists of all non-cirrhotic randomized patients who received at least one dose of study treatment.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Discontinuing From Study Treatment Due to AEs</title>
        <description>The number of non-cirrhotic participants withdrawing from study treatment due to AEs during the active Vaniprevir/PBO treatment and 14-day follow-up periods was monitored for each treatment regimen.</description>
        <time_frame>Up to 48 weeks</time_frame>
        <population>The All-Patients-as-Treated (APaT) population was employed for safety analyses. The APaT population consists of all randomized non-cirrhotic patients who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>24- or 48-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
            <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 or 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>24-wk Vaniprevir 600 mg, 24-wk PBO + Peg-IFN/RBV</title>
            <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</title>
            <description>Vaniprevir 300 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
            <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
          </group>
          <group group_id="O5">
            <title>48-wk PBO + Peg-IFN/RBV</title>
            <description>PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing From Study Treatment Due to AEs</title>
          <description>The number of non-cirrhotic participants withdrawing from study treatment due to AEs during the active Vaniprevir/PBO treatment and 14-day follow-up periods was monitored for each treatment regimen.</description>
          <population>The All-Patients-as-Treated (APaT) population was employed for safety analyses. The APaT population consists of all randomized non-cirrhotic patients who received at least one dose of study treatment.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 300 mg b.i.d.</title>
        <description>The percentage of non-cirrhotic participants treated with Vaniprevir 300 mg b.i.d. with undetectable HCV RNA 24 weeks after completing treatment was determined.</description>
        <time_frame>72 weeks</time_frame>
        <population>The Full Analysis Set (FAS) population consists of all non-cirrhotic participants who received at least 1 dose of study treatment, have post-dose endpoint data, and have baseline data for measures that require baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</title>
            <description>Vaniprevir 300 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>48-wk PBO + Peg-IFN/RBV</title>
            <description>PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 300 mg b.i.d.</title>
          <description>The percentage of non-cirrhotic participants treated with Vaniprevir 300 mg b.i.d. with undetectable HCV RNA 24 weeks after completing treatment was determined.</description>
          <population>The Full Analysis Set (FAS) population consists of all non-cirrhotic participants who received at least 1 dose of study treatment, have post-dose endpoint data, and have baseline data for measures that require baseline data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Adjusted difference in percentage</param_type>
            <param_value>47.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.2</ci_lower_limit>
            <ci_upper_limit>63.2</ci_upper_limit>
            <estimate_desc>Adjusted difference subtracts the percentage of PBO-treated participants (i.e., 19.0%) that achieved SVR24 and stratifies by prior treatment response.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving cEVR</title>
        <description>The percentage of non-cirrhotic participants with complete early viral response (cEVR; undetectable HCV RNA at Week 12) was determined for each Vaniprevir dose. Since each of the Vaniprevir 600 mg arms had the same treatment history at this point in the study, the data were pooled for analysis.</description>
        <time_frame>Up to Week 60</time_frame>
        <population>The Full Analysis Set (FAS) population consists of all non-cirrhotic participants who received at least 1 dose of study treatment, have post-dose endpoint data, and have baseline data for measures that require baseline data. The 3 Vaniprevir 600 mg b.i.d. arms were combined in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>24- or 48-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
            <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 or 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</title>
            <description>Vaniprevir 300 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PBO + Peg-IFN/RBV</title>
            <description>PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving cEVR</title>
          <description>The percentage of non-cirrhotic participants with complete early viral response (cEVR; undetectable HCV RNA at Week 12) was determined for each Vaniprevir dose. Since each of the Vaniprevir 600 mg arms had the same treatment history at this point in the study, the data were pooled for analysis.</description>
          <population>The Full Analysis Set (FAS) population consists of all non-cirrhotic participants who received at least 1 dose of study treatment, have post-dose endpoint data, and have baseline data for measures that require baseline data. The 3 Vaniprevir 600 mg b.i.d. arms were combined in this analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0"/>
                    <measurement group_id="O2" value="85.4"/>
                    <measurement group_id="O3" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted difference in percentage</param_type>
            <param_value>82.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69.5</ci_lower_limit>
            <ci_upper_limit>90.2</ci_upper_limit>
            <estimate_desc>Adjusted difference subtracts the percentage of PBO-treated participants (i.e., 9.5%) that achieved cEVR and stratifies by prior treatment response.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted difference in percentage</param_type>
            <param_value>76.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>60.1</ci_lower_limit>
            <ci_upper_limit>86.7</ci_upper_limit>
            <estimate_desc>Adjusted difference subtracts the percentage of PBO-treated participants (i.e., 9.5%) that achieved cEVR and stratifies by prior treatment response.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SVR24 After 24 Weeks of Vaniprevir 600 mg b.i.d.</title>
        <description>The percentage of participants achieving SVR24 after the 24-week Vaniprevir 600 mg b.i.d. regimen at Week 48 was compared to the control regimen.</description>
        <time_frame>Week 48</time_frame>
        <population>The Full Analysis Set (FAS) population consists of all non-cirrhotic participants who received at least 1 dose of study treatment, have post-dose endpoint data, and have baseline data for measures that require baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>24- or 48-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
            <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 or 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>48-wk PBO + Peg-IFN/RBV</title>
            <description>PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SVR24 After 24 Weeks of Vaniprevir 600 mg b.i.d.</title>
          <description>The percentage of participants achieving SVR24 after the 24-week Vaniprevir 600 mg b.i.d. regimen at Week 48 was compared to the control regimen.</description>
          <population>The Full Analysis Set (FAS) population consists of all non-cirrhotic participants who received at least 1 dose of study treatment, have post-dose endpoint data, and have baseline data for measures that require baseline data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1"/>
                    <measurement group_id="O2" value="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted difference in percentage</param_type>
            <param_value>35.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.5</ci_lower_limit>
            <ci_upper_limit>53.4</ci_upper_limit>
            <estimate_desc>Adjusted difference subtracts the percentage of PBO patients (36.6%) with undetectable HCV RNA at Week 48 and stratifies by prior treatment response.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were monitored for 50 weeks (48 weeks of active treatment and 2 weeks of follow-up) and serious AEs were monitored for 18 months.</time_frame>
      <desc>AEs were monitored and presented for the combined NC and C participant populations.</desc>
      <group_list>
        <group group_id="E1">
          <title>24-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
          <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and peg-IFN 180 mcg injection once weekly for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>24-wk Vaniprevir 600 mg, 24-wk PBO + Peg-IFN/RBV</title>
          <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and peg-IFN 180 mcg injection once weekly for an additional 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>48-wk Vaniprevir 300 mg + Peg-IFN/RBV</title>
          <description>Vaniprevir 300 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
        </group>
        <group group_id="E4">
          <title>48-wk Vaniprevir 600 mg + Peg-IFN/RBV</title>
          <description>Vaniprevir 600 mg and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
        </group>
        <group group_id="E5">
          <title>48-wk PBO + Peg-IFN/RBV</title>
          <description>PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (v. 15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Retinal vascular thorombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatomyositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (v. 15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E2" events="23" subjects_affected="15" subjects_at_risk="56"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="6" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E3" events="25" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" events="10" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="61"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="23" subjects_at_risk="56"/>
                <counts group_id="E2" events="34" subjects_affected="26" subjects_at_risk="56"/>
                <counts group_id="E3" events="41" subjects_affected="15" subjects_at_risk="56"/>
                <counts group_id="E4" events="48" subjects_affected="33" subjects_at_risk="61"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="56"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E4" events="11" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="31" subjects_affected="26" subjects_at_risk="56"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="56"/>
                <counts group_id="E3" events="30" subjects_affected="20" subjects_at_risk="56"/>
                <counts group_id="E4" events="50" subjects_affected="39" subjects_at_risk="61"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="56"/>
                <counts group_id="E2" events="30" subjects_affected="16" subjects_at_risk="56"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E4" events="26" subjects_affected="17" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="56"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="56"/>
                <counts group_id="E4" events="14" subjects_affected="13" subjects_at_risk="61"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="31" subjects_affected="26" subjects_at_risk="56"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="56"/>
                <counts group_id="E3" events="29" subjects_affected="25" subjects_at_risk="56"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="61"/>
                <counts group_id="E5" events="20" subjects_affected="18" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="56"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="56"/>
                <counts group_id="E4" events="21" subjects_affected="15" subjects_at_risk="61"/>
                <counts group_id="E5" events="14" subjects_affected="12" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mucosal dryness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E5" events="18" subjects_affected="14" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="8" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="56"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="56"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="61"/>
                <counts group_id="E5" events="13" subjects_affected="11" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="56"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="61"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="36" subjects_affected="23" subjects_at_risk="56"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="56"/>
                <counts group_id="E3" events="40" subjects_affected="28" subjects_at_risk="56"/>
                <counts group_id="E4" events="34" subjects_affected="23" subjects_at_risk="61"/>
                <counts group_id="E5" events="26" subjects_affected="20" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="56"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="61"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="56"/>
                <counts group_id="E4" events="15" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E2" events="28" subjects_affected="20" subjects_at_risk="56"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E4" events="19" subjects_affected="17" subjects_at_risk="61"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="56"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="61"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="56"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="56"/>
                <counts group_id="E3" events="23" subjects_affected="17" subjects_at_risk="56"/>
                <counts group_id="E4" events="23" subjects_affected="21" subjects_at_risk="61"/>
                <counts group_id="E5" events="15" subjects_affected="14" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E4" events="22" subjects_affected="20" subjects_at_risk="61"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

